Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore.,Journal of Gynecologic Oncology

当前位置： X-MOL 学术 › J. Gynecol. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore.
Journal of Gynecologic Oncology ( IF 3.4 ) Pub Date : 2021-01-18 , DOI: 10.3802/jgo.2021.32.e27
David Sp Tan _{1,

2} , Jack Junjie Chan ₃ , Robert Hettle ₄ , Wrik Ghosh ₅ , Amrita Viswambaram ₅ , Cindy Chen Yu ₆

Affiliation

To evaluate the cost-effectiveness of olaparib as a maintenance treatment versus routine surveillance (RS) in patients with BRCA mutated (BRCAm) advanced ovarian cancer (OC) following response to first-line platinum-based chemotherapy in Singapore.

中文翻译：